Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL22263593 | 0.98 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Zinc Ion SCHEMBL927086 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Lithium Ion SCHEMBL11350422 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| SCHEMBL927005 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| SCHEMBL2590649 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| SCHEMBL31512217 | 0.95 | KDM4E (0.46) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512212 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512215 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512211 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR | |
| Water SCHEMBL31512210 | 0.93 | KDM4E (0.44) | KDM4EMAPK1HIF1ABBOX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383520-B2 | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2025-08-12 | — | — | US | claimed |
| CN-119431198-A | Preparation method of magnesium acetyltaurate | 苏州满元生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3750873-B1 | METHOD FOR MANUFACTURING MAGNESIUM N-ACETYL-TAURINATE | SYNAPHARM IND SYNTHESIS (BE) | 2023-12-20 | — | — | EP | claimed |
| EP-4228609-A1 | DIRECTLY ADMINISTERED GRANULAR COMPOSITION HAVING A COMBINATION OF DELAYED-RELEASE AND RAPID-RELEASE MAGNESIUM, AND PROCESSES FOR THE PRODUCTION THEREOF | HERMES PHARMA GmbH (DE) | 2023-08-23 | — | — | EP | claimed |
| WO-2023057451-A1 | DIRECTLY ADMINISTERED GRANULAR COMPOSITION HAVING A COMBINATION OF DELAYED-RELEASE AND RAPID-RELEASE MAGNESIUM, AND PROCESSES FOR THE PRODUCTION THEREOF | HERMES PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | claimed |
| US-20220218633-A1 | COMPOUND AND COMPOSITION FOR USE IN THE TREATMENT OF PREMENSTRUAL SYNDROME AND/OR PREMENSTRUAL DYSPHORIC DISORDER | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2022-07-14 | — | — | US | claimed |
| EP-3738596-B1 | COMPOUND AND COMPOSITION FOR USE IN THE TREATMENT OF PREMENSTRUAL SYNDROME AND/OR PREMENSTRUAL DYSPHORIC DISORDER | SYNAPHARM IND SYNTHESIS (BE) | 2022-03-16 | — | — | EP | claimed |
| WO-2020229443-A1 | COMPOUND AND COMPOSITION FOR USE IN THE TREATMENT OF PREMENSTRUAL SYNDROME AND/OR PREMENSTRUAL DYSPHORIC DISORDER | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2020-11-19 | — | — | WO | claimed |
| EP-3694505-A1 | COMPOUND AND COMPOSITION FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM CHARACTERISED BY A DECLINE IN NEURONAL PLASTICITY, IN PARTICULAR CHARACTERISED BY A DECLINE IN SYNAPTIC PLASTICITY | Synapharm Industrial Synthesis (BE) | 2020-08-19 | — | — | EP | claimed |
| EP-4228609-B1 | DIRECT GRANULES WITH A COMBINATION OF RETARDED AND FAST-RELEASING MAGNESIUM | HERMES PHARMA GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026018281-A1 | A SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DISORDERS RELATED TO CENTRAL NERVOUS SYSTEM (CNS) EXCITABILITY. | Celagenex Research (India) Pvt. Ltd. (IN) | 2026-01-22 | — | — | WO | disclosed |
| US-12383520-B2 | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2025-08-12 | — | — | US | disclosed |
| CN-119431198-A | Preparation method of magnesium acetyltaurate | 苏州满元生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119431198-A | Preparation method of magnesium acetyltaurate | 苏州满元生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2019072568-A1 | COMPOUND AND COMPOSITION FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM CHARACTERISED BY A DECLINE IN NEURONAL PLASTICITY, IN PARTICULAR CHARACTERISED BY A DECLINE IN SYNAPTIC PLASTICITY | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019072568-A1 | COMPOUND AND COMPOSITION FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM CHARACTERISED BY A DECLINE IN NEURONAL PLASTICITY, IN PARTICULAR CHARACTERISED BY A DECLINE IN SYNAPTIC PLASTICITY | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2019-04-18 | — | — | WO | disclosed |
| EP-2324832-B2 | Nutritional supplement while taking hormonal contraceptives | BIOGENA NATURPRODUKTE GMBH & CO KG (AT) | 2016-11-30 | — | — | EP | disclosed |
| EP-2324832-B1 | Nutritional supplement while taking hormonal contraceptives | BIOGENA NATURPRODUKTE GMBH & CO KG (AT) | 2014-05-14 | — | — | EP | disclosed |
| EP-2324832-A1 | Nutritional supplement while taking hormonal contraceptives | Biogena Naturprodukte GmbH & Co KG (AT) | 2011-05-25 | — | — | EP | disclosed |
| US-4267194-A | Calcium derivatives of taurine having reinforced neuro-muscular activity | LES LABORATORIES MERAM (FR) | 1981-05-12 | — | — | US | disclosed |